{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T08:34:07Z","timestamp":1793003647970,"version":"4.5.0"},"reference-count":23,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomed Rep"],"DOI":"10.3892\/br.2026.2196","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:56:47Z","timestamp":1788256607000},"page":"1-8","source":"Crossref","is-referenced-by-count":1,"title":["Oxaliplatin\u2011induced autoimmune\u2011like hepatitis: A case report highlighting the role of clinical pharmacists"],"prefix":"10.3892","volume":"25","author":[{"given":"Xiao","family":"Zeng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First College of Clinical Medicine Science, China Three Gorges University, Yichang, Hubei 443000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Yichang Central People's Hospital, Yichang, Hubei 443000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilan","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First College of Clinical Medicine Science, China Three Gorges University, Yichang, Hubei 443000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"key20261026100056_b1-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1056\/NEJMra1816149","article-title":"Drug-induced liver injury - types and phenotypes","volume":"381","author":"Hoofnagle","year":"2019","journal-title":"N Engl J Med"},{"key":"key20261026100056_b2-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"key20261026100056_b3-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/ueg2.12499","article-title":"Defining characteristics and long-term prognosis of drug-induced autoimmune-like hepatitis: A retrospective cohort study","volume":"12","author":"Chung","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"key20261026100056_b4-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jhep.2023.04.033","article-title":"Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report","volume":"79","author":"Andrade","year":"2023","journal-title":"J Hepatol"},{"key":"key20261026100056_b5-BR-25-5-02196","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrd1287","article-title":"Oxaliplatin","volume":"3","author":"Graham","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"key20261026100056_b6-BR-25-5-02196","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1200\/JCO.22.02773","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"41","author":"de Gramont","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20261026100056_b7-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1200\/JCO.19.00281","article-title":"Duration of oxaliplatin-containing adjuvant therapy for stage III colon cancer: ASCO clinical practice guideline","volume":"37","author":"Lieu","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20261026100056_b8-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s00415-020-09942-w","article-title":"Oxaliplatin-induced peripheral neuropathy: Clinical features, mechanisms, prevention and treatment","volume":"268","author":"Kang","year":"2021","journal-title":"J Neurol"},{"key":"key20261026100056_b9-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.14218\/JCTH.2023.00399","article-title":"Predictive model of oxaliplatin-induced liver injury based on artificial neural network and logistic regression","volume":"11","author":"Huang","year":"2023","journal-title":"J Clin Transl Hepatol"},{"issue":"757196","key":"key20261026100056_b10-BR-25-5-02196","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.757196","article-title":"Safety profile of oxaliplatin in 3,687 patients with cancer in China: A post-marketing surveillance study","volume":"11","author":"Yu","year":"2021","journal-title":"Front Oncol"},{"key":"key20261026100056_b11-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more \u2018personalized\u2019 approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"key20261026100056_b12-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"366","DOI":"10.6004\/jnccn.2024.0041","article-title":"NCCN guidelines\u00ae insights: Rectal cancer, version 3.2024","volume":"22","author":"Benson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"key20261026100056_b13-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: Drug-induced liver injury","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"key20261026100056_b14-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: Autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"key20261026100056_b15-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"key20261026100056_b16-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/hep.23577","article-title":"Causality assessment in drug-induced liver injury using a structured expert opinion process: Comparison to the roussel-uclaf causality assessment method","volume":"51","author":"Rockey","year":"2010","journal-title":"Hepatology"},{"key":"key20261026100056_b17-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.14309\/ajg.0000000000001836","article-title":"RECAM: A new and improved, computerized causality assessment tool for DILI diagnosis","volume":"117","author":"Hayashi","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"key20261026100056_b18-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis","volume":"51","author":"Bj\u00f6rnsson","year":"2010","journal-title":"Hepatology"},{"key":"key20261026100056_b19-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/hep.26175","article-title":"LiverTox: A website on drug-induced liver injury","volume":"57","author":"Hoofnagle","year":"2013","journal-title":"Hepatology"},{"key":"key20261026100056_b20-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1365-2559.2010.03511.x","article-title":"Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis","volume":"56","author":"Rubbia-Brandt","year":"2010","journal-title":"Histopathology"},{"key":"key20261026100056_b21-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.clcc.2012.01.003","article-title":"Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A phase II study of the Spanish cooperative group for the treatment of digestive tumors","volume":"11","author":"Benavides","year":"2012","journal-title":"Clin Colorectal Cancer"},{"key":"key20261026100056_b22-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1245\/s10434-012-2438-8","article-title":"Chemotherapy-associated liver injury in patients with colorectal liver metastases: A systematic review and meta-analysis","volume":"19","author":"Robinson","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"key20261026100056_b23-BR-25-5-02196","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jhep.2013.04.014","article-title":"Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model","volume":"59","author":"Robinson","year":"2013","journal-title":"J Hepatol"}],"container-title":["Biomedical Reports"],"original-title":[],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T08:01:02Z","timestamp":1793001662000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/br.2026.2196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.3892\/br.2026.2196","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}